Schonkeren, S
Exenatide is resistant to DPP-4 inactivation and has a half-life of approximately 2.4 h after s.c
Contact your GP or diabetes specialist nurse if you experience: Persistent or severe nausea and vomiting that prevents adequate food or fluid intake, as this increases the risk of dehydration and hypoglycaemia Abdominal pain , particularly if constant or worsening Signs of dehydration including reduced urination, dizziness, dry mouth, or confusion Unexplained weight loss beyond what is expected from the medication's appetite-suppressing effects Blood in vomit or stools , which requires urgent assessment Symptoms of hypoglycaemia (shakiness, sweating, confusion) if taking Rybelsus alongside sulfonylureas or insulin Right upper quadrant pain, fever, or jaundice , which could indicate gallbladder diseasea known risk with GLP-1 receptor agonists New or worsening visual symptoms if you have pre-existing diabetic retinopathy Seek immediate medical attention (call 999 or attend A&E) if you develop: Severe, persistent abdominal pain radiating to the back (potential pancreatitis)stop taking Rybelsus immediately if pancreatitis is suspected Signs of severe allergic reaction (difficulty breathing, facial swelling, severe rash) Symptoms suggesting diabetic ketoacidosis (excessive thirst, frequent urination, confusion, fruity breath odour)this is rare but may occur, particularly if insulin has been rapidly reduced or discontinued If sulphur burps and other gastrointestinal symptoms persist beyond the first 4-6 weeks of therapy despite dietary modifications, or if they significantly impair quality of life, schedule a routine appointment to discuss management options
echo time (TE) = 11 ms
10.1002/hep.28574 205 SunX.OuZ.ChenR.NiuX.ChenD.KangR.et al (2016b)
